Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Von Willebrand Disease (VWD) represents the most prevalent inherited bleeding disorder affecting the human population, characterized by a fundamental defect in primary hemostasis. It is caused by a quantitative deficiency or qualitative dysfunction of the von Willebrand factor (VWF), a large, complex plasma glycoprotein essential for blood clotting.
In a physiologically normal hemostatic system, the body responds to vascular injury through a rapid sequence of events designed to seal the breach and prevent blood loss. VWF plays a pivotal, dual role in this process. First, it acts as a molecular bridge, mediating the adhesion of platelets to the exposed subendothelial collagen matrix at the site of vessel injury. Second, it serves as a specific carrier protein for Factor VIII (FVIII), a critical enzyme in the intrinsic coagulation cascade, protecting it from premature proteolytic degradation in the circulation.
When VWF is absent, reduced, or functionally impaired, the formation of the initial platelet plug is delayed or ineffective, and Factor VIII levels may drop significantly, leading to a spectrum of bleeding tendencies. Unlike hemophilia, which is X-linked and primarily affects males, VWD is autosomal, affecting both males and females with equal frequency, although clinical presentation is often more pronounced in females due to hemostatic challenges such as menstruation and childbirth. At Liv Hospital, we conceptualize VWD not merely as a clotting factor deficiency, but as a complex biological disorder of endothelial and platelet interaction requiring precise molecular characterization.
The disease is named after Dr. Erik von Willebrand, a Finnish physician who first described the condition in 1926. He investigated a large family living on the Åland Islands in the Baltic Sea, many of whom suffered from severe bleeding symptoms. Dr. von Willebrand originally termed the condition “hereditary pseudo-hemophilia” because, while the clinical bleeding resembled hemophilia, it affected both sexes and was associated with a prolonged bleeding time, a test of platelet function, rather than the clotting time abnormalities seen in classic hemophilia.
To fully grasp the pathology of VWD, one must appreciate the complex lifecycle of the VWF protein.
The function of VWF is integral to the very first steps of clot formation.
The International Society on Thrombosis and Haemostasis (ISTH) classifies VWD into three primary categories based on the pathophysiology of the defect. This classification is not merely academic; it dictates the clinical management, as treatments effective for one type may be ineffective or even dangerous for another.
This is the most common form, representing approximately 70 to 80 percent of all clinical cases.
This category accounts for 20 to 25 percent of cases and represents qualitative defects. The body produces normal or near-normal amounts of VWF, but the protein structure is mutated, preventing it from functioning correctly. Type 2 is subdivided into four distinct variants.
This is the rarest and most severe form, affecting approximately one in one million individuals.
This is the rarest and most severe form, affecting approximately one in one million individuals.
Unlike the inherited forms, AVWS is a rare bleeding disorder that develops later in life. It is not caused by germline genetic mutations but by underlying pathologic processes that increase the clearance or inhibit the function of VWF.
A critical physiological variable in VWD diagnosis is the patient’s ABO blood type. Genetic determinants of the ABO blood group located on chromosome 9 exert a significant influence on plasma VWF levels.
Send us all your questions or requests, and our expert team will assist you.
No, although they are similar, VWD is caused by a problem with the Von Willebrand protein, while hemophilia is caused by a lack of Factor VIII or IX.
Yes, especially in Type 1 VWD, where symptoms can be very mild, it might appear to skip a generation if a carrier parent has no obvious symptoms.
Generally, the type of VWD remains constant, but VWF levels can rise with age, potentially reducing bleeding symptoms in older adults.
It is rarely fatal with modern medical management, although severe forms like Type 3 can cause life-threatening bleeding if not treated promptly.
We are looking into how desmopressin changes medicine. It’s a synthetic hormone that has made a big difference in treating many health issues. Desmopressin is
Blood donation is a key act that saves many lives. But, some medical conditions, like hemophilia, make it risky for donors and recipients. Hemophilia stops
Uncontrolled bleeding is a big risk, mainly for those on anticoagulants. We’ll look at medicines to stop or prevent bleeding. This includes anticoagulants like warfarin
Diagnosing some blood disorders is tough. Conditions like Von Willebrand disease and myelodysplastic syndromes show symptoms that look like other common health issues. This makes
Inherited bleeding disorders affect thousands worldwide. Hemophilia and von Willebrand disease are the most common. Hemophilia makes it hard for blood to clot, leading to
Rare bleeding disorders affect millions worldwide, leaving patients and healthcare providers searching for answers. One in 10,000 people are born with a rare bleeding disorder,
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
